Doing immuno-oncology drug discovery in a large pharmaceutical company means there is almost always a desire for more and different data to drive decision-making on potential new therapeutic compounds. That was exactly the situation a Senior Research Fellow at a Fortune 500 pharmaceutical company found himself in when he decided to work with PharmaLegacy to assess the activity of their novel compounds.

Download the case study and see what he had to say about his experiences working with PharmaLegacy as their immuno-oncology CRO.